Latest neutropenia Stories

Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that a GlycoPEG-GCSF Phase I clinical abstract submitted by the Company's collaborative partner, BioGeneriX AG, has been accepted for a poster presentation at the IXth World Conference on Clinical Pharmacology and Therapeutics. The International Union of Basic and Clinical Pharmacology is hosting this Annual Scientific Meeting in Quebec City, Canada from July 27-August 1, 2008. The abstract is entitled "GlycoPEGylated G-CSF XM22...

RICHMOND, Va., July 10, 2008 /PRNewswire-FirstCall/ -- Insmed Inc. , a developer of follow-on biologics and biopharmaceuticals for unmet medical needs, today announced that it has demonstrated the bioequivalence of INS-19, the company's recombinant human granulocyte colony stimulating factor (G-CSF), compared to Neupogen(R), an FDA-approved G-CSF product for the treatment of neutropenia that recorded 2007 sales of approximately $1 billion. Human bioequivalence studies utilize...

By Stewart, Susan Context.-Pulmonary infections are common and often life- threatening in solid organ and stem cell transplant recipients. Understanding their pathology is critical to making improvements in care and survival as well as in surgical techniques, immunosuppression management, prophylaxis, and treatment. Pulmonary infections are particularly common and serious in the susceptible population of lung transplant recipients. Objective.-To summarize recent updates in the field for...

By Auer, Rebecca Infection is the most common cause of neutrophilia, says Dr Rebecca Auer Neutrophilia is an increase in circulating neutrophils above that expected in a healthy individual of the same age, sex, race and physiological status. TMs represents an increase in the neutrophil count above 7.5 ? 1e'/1 and is one of the most frequently observed changes in the FBC. It is usually due either to a redistribution of white cells or an increase hi bone marrow output. Neutrophilia can occur...